Positron Corporation (POSC)

[JackStraw]

NEWS OUT ON POSC

Positron Corporation Announces Appointment of Medical Director
Dec 16, 2008 4:21:00 PM

--(BUSINESS WIRE)-- Positron Corporation (OTC BB:POSC). Positron Corporation's Board of Directors has appointed Michael E. Merhige, M.D. as their Medical Director. Dr. Merhige will be responsible for providing clinical leadership and has designated his practice as a signature show site for Positron software developers and customers. Dr. Merhige has performed and interpreted over 25,000 cardiac PET scans, and has been involved in cardiac PET for 22 years. He is currently Director of the Heart Center of Niagara, which specializes in the noninvasive management of coronary disease guided by PET myocardial perfusion imaging. He has authored numerous publications in the field of cardiac molecular imaging, and is an acknowledged expert in the field.

Dr. Merhige said: "I am delighted to accept the position of Medical Director for Positron Corporation and to work closely with Positron's President, Joseph Oliverio. I have long noted that Positron equipment provides the best cardiac perfusion images using Rb-82, as well as the best cardiac software. I anticipate with the upcoming release of Positron's cost effective PET only alternative that cardiac PET will become the procedure of choice for managing patients with coronary disease because of its cost efficacy when compared to conventional SPECT imaging. My practice has noted a significant reduction in the utilization of subsequent coronary angiograms and bypass surgery, reduction in coronary disease management costs, and equivalent or better rates of outcomes when PET is used in place of SPECT imaging, with Positron equipment. "

Mr. Oliverio President of Positron said, "Dr. Merhige brings an essential clinical understanding of PET to Positron and will help us position our products to be widely accepted in the world markets. The addition of his site as our premier demonstration project will serve as an excellent example of the potential efficacy of PET in a rural hospital setting"

About Positron

Positron Corporation is a vertically integrated company in the field of Cardiac Nuclear Medicine. The Company operates through two segments: Molecular Imaging Devices and Radiopharmaceutical Products. The Molecular Imaging Devices segment provides PET scanners and SPECT cameras; the Pharmaceutical Products segment offers world's first robotic systems for distribution and delivery of radiopharmaceuticals and provides radiopharmaceutical agents used for the diagnosis of cardiac diseases. The Company is able to offer a total customer solution which includes low cost molecular imaging devices, disease specific software, radiopharmaceutical distribution and delivery systems, and radiopharmaceuticals agents for Cardiac Nuclear Medicine. Additional information can be found at http://www.positron.com

Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. The words "expect," "anticipate," "intend," "plan," "believe," "seek," "estimate," and similar expressions are intended to identify such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.




Source: Positron Corporation


----------------------------------------------
Positron Corporation
Joe Oliverio
President
281-492-7100